Sanofi CEO Paul Hudson stressed at Davos the value of AI in drug development decisions, highlighting that AI agents provide dispassionate recommendations without career bias. The company uses AI insights to guide progression of drug candidates through development phases, interpreting AI's input as a sobering, objective perspective. Hudson emphasized AI's role in accelerating discovery and making critical choices, noting its nearly three-year application aligns with roughly one-third of their drug discovery phase timeline. Other industry leaders echoed optimism about AI complementing human expertise rather than replacement.